GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ChemoMetec AS (FRA:CHY) » Definitions » Total Liabilities

ChemoMetec AS (FRA:CHY) Total Liabilities : €17.73 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is ChemoMetec AS Total Liabilities?

ChemoMetec AS's Total Liabilities for the quarter that ended in Dec. 2024 was €17.73 Mil.

ChemoMetec AS's quarterly Total Liabilities increased from Dec. 2023 (€12.72 Mil) to Jun. 2024 (€14.92 Mil) and increased from Jun. 2024 (€14.92 Mil) to Dec. 2024 (€17.73 Mil).

ChemoMetec AS's annual Total Liabilities declined from Jun. 2022 (€19.36 Mil) to Jun. 2023 (€16.78 Mil) and declined from Jun. 2023 (€16.78 Mil) to Jun. 2024 (€14.92 Mil).


ChemoMetec AS Total Liabilities Historical Data

The historical data trend for ChemoMetec AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoMetec AS Total Liabilities Chart

ChemoMetec AS Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.10 10.75 19.36 16.78 14.92

ChemoMetec AS Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.38 16.78 12.72 14.92 17.73

ChemoMetec AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ChemoMetec AS's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.201+(0.131+1.588
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=14.92

Total Liabilities=Total Assets (A: Jun. 2024 )-Total Equity (A: Jun. 2024 )
=90.664-75.744
=14.92

ChemoMetec AS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.453+(0.625+0.653
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=17.73

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=97.915-80.183
=17.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoMetec AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of ChemoMetec AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoMetec AS Business Description

Traded in Other Exchanges
Address
Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.